Adelow C, Andersson T, Ahlbom A, Tomson T Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012 Feb 7;78(6):396-401. doi: 10.1212/WNL.0b013e318245f461. Epub 2012 Jan 25.
An N, Zhao W, Liu Y, Yang X, Chen P Elevated serum miR-106b and miR-146a in patients with focal and generalized epilepsy. Epilepsy Res. 2016 Nov;127:311-316. doi: 10.1016/j.eplepsyres.2016.09.019. Epub 2016 Sep 26.
Appleton RE, Freeman A, Cross JH Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline. Arch Dis Child. 2012 Dec;97(12):1073-6. doi: 10.1136/archdischild-2012-302822. Epub 2012 Oct 6.
Aston C, Jiang L, Sokolov BP Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. 2005 Mar;10(3):309-22. doi: 10.1038/sj.mp.4001565.
Balan S, Sathyan S, Radha SK, Joseph V, Radhakrishnan K, Banerjee M GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenet Genomics. 2013 Nov;23(11):605-10. doi: 10.1097/FPC.0000000000000000.
Baldin E, Hauser WA, Pack A, Hesdorffer DC Stress is associated with an increased risk of recurrent seizures in adults. Epilepsia. 2017 Jun;58(6):1037-1046. doi: 10.1111/epi.13741. Epub 2017 Apr 18.
Beghi E Social functions and socioeconomic vulnerability in epilepsy. Epilepsy Behav. 2019 Nov;100(Pt B):106363. doi: 10.1016/j.yebeh.2019.05.051. Epub 2019 Jul 9.
Beniczky SA, Viken J, Jensen LT, Andersen NB Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure. 2012 Jul;21(6):471-2. doi: 10.1016/j.seizure.2012.04.002. Epub 2012 Apr 26.
Bien CG, Szinay M, Wagner J, Clusmann H, Becker AJ, Urbach H Characteristics and surgical outcomes of patients with refractory magnetic resonance imaging-negative epilepsies. Arch Neurol. 2009 Dec;66(12):1491-9. doi: 10.1001/archneurol.2009.283.
Brodie MJ, Richens A, Yuen AW Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995 Feb 25;345(8948):476-9. doi: 10.1016/s0140-6736(95)90581-2. Erratum In: Lancet 1995 Mar 11;345(8950):662.
Chung S, Wang N, Hank N Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007 Jun;16(4):296-304. doi: 10.1016/j.seizure.2007.01.004. Epub 2007 Jan 30.
Clossen BL, Reddy DS Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1519-1538. doi: 10.1016/j.bbadis.2017.02.003. Epub 2017 Feb 5.
Darrah SD, Miller MA, Ren D, Hoh NZ, Scanlon JM, Conley YP, Wagner AK Genetic variability in glutamic acid decarboxylase genes: associations with post-traumatic seizures after severe TBI. Epilepsy Res. 2013 Feb;103(2-3):180-94. doi: 10.1016/j.eplepsyres.2012.07.006. Epub 2012 Jul 26.
DiMatteo MR, Lepper HS, Croghan TW Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7. doi: 10.1001/archinte.160.14.2101.
Dmitrienko A, D'Agostino R Sr Traditional multiplicity adjustment methods in clinical trials. Stat Med. 2013 Dec 20;32(29):5172-218. doi: 10.1002/sim.5990. Epub 2013 Sep 30.
Doucet G, Osipowicz K, Sharan A, Sperling MR, Tracy JI Extratemporal functional connectivity impairments at rest are related to memory performance in mesial temporal epilepsy. Hum Brain Mapp. 2013 Sep;34(9):2202-16. doi: 10.1002/hbm.22059. Epub 2012 Apr 16.
Ellis CA, Petrovski S, Berkovic SF Epilepsy genetics: clinical impacts and biological insights. Lancet Neurol. 2020 Jan;19(1):93-100. doi: 10.1016/S1474-4422(19)30269-8. Epub 2019 Sep 4.
Fazel S, Wolf A, Langstrom N, Newton CR, Lichtenstein P Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013 Nov 16;382(9905):1646-54. doi: 10.1016/S0140-6736(13)60899-5. Epub 2013 Jul 22.
Gomez-Eguilaz M, Ramon-Trapero JL, Perez-Martinez L, Blanco JR The beneficial effect of probiotics as a supplementary treatment in drug-resistant epilepsy: a pilot study. Benef Microbes. 2018 Dec 7;9(6):875-881. doi: 10.3920/BM2018.0018. Epub 2018 Sep 10.
Helmstaedter C, Aldenkamp AP, Baker GA, Mazarati A, Ryvlin P, Sankar R Disentangling the relationship between epilepsy and its behavioral comorbidities - the need for prospective studies in new-onset epilepsies. Epilepsy Behav. 2014 Feb;31:43-7. doi: 10.1016/j.yebeh.2013.11.010. Epub 2013 Dec 13.
Helmstaedter C, Witt JA Epilepsy and cognition - A bidirectional relationship? Seizure. 2017 Jul;49:83-89. doi: 10.1016/j.seizure.2017.02.017. Epub 2017 Mar 1.
Howren MB, Lamkin DM, Suls J Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009 Feb;71(2):171-86. doi: 10.1097/PSY.0b013e3181907c1b. Epub 2009 Feb 2.
International League Against Epilepsy Consortium on Complex Epilepsies Electronic address: epilepsy-austin@unimelb.edu.au. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol. 2014 Sep;13(9):893-903. doi: 10.1016/S1474-4422(14)70171-1. Epub 2014 Jul 30.
Johnson AL, McLeish AC, Shear PK, Sheth A, Privitera M The role of cigarette smoking in epilepsy severity and epilepsy-related quality of life. Epilepsy Behav. 2019 Apr;93:38-42. doi: 10.1016/j.yebeh.2019.01.041. Epub 2019 Mar 1.
Kanner AM Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control? Neurochem Res. 2017 Jul;42(7):2071-2076. doi: 10.1007/s11064-017-2331-8. Epub 2017 Jul 1.
Kanner AM Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol. 2013 Apr;26(2):208-13. doi: 10.1097/WCO.0b013e32835ee579.
Kanner AM Psychiatric comorbidities and epilepsy: is it the old story of the chicken and the egg? Ann Neurol. 2012 Aug;72(2):153-5. doi: 10.1002/ana.23679. No abstract available.
Kanner AM Psychiatric comorbidities in new onset epilepsy: Should they be always investigated? Seizure. 2017 Jul;49:79-82. doi: 10.1016/j.seizure.2017.04.007. Epub 2017 Apr 14.
Kauffman MA, Levy EM, Consalvo D, Mordoh J, Kochen S GABABR1 (G1465A) gene variation and temporal lobe epilepsy controversy: new evidence. Seizure. 2008 Sep;17(6):567-71. doi: 10.1016/j.seizure.2007.12.006. Epub 2008 Feb 5.
Kim M, Kim YS, Kim DH, Yang TW, Kwon OY Major depressive disorder in epilepsy clinics: A meta-analysis. Epilepsy Behav. 2018 Jul;84:56-69. doi: 10.1016/j.yebeh.2018.04.015. Epub 2018 May 10.
Klein P, Tyrlikova I, Brazdil M, Rektor I Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(2):283-95. doi: 10.1517/14656566.2016.1135129. Epub 2016 Jan 13.
Leach JP, Brodie MJ New antiepileptic drugs--an explosion of activity. Seizure. 1995 Mar;4(1):5-17. doi: 10.1016/s1059-1311(05)80074-3.
Li J, Lin H, Zhu X, Li L, Wang X, Sun W, Wu X, Liu A, Niu F, Wang Y, Liu Y Association study of functional polymorphisms in serotonin transporter gene with temporal lobe epilepsy in Han Chinese population. Eur J Neurol. 2012 Feb;19(2):351-3. doi: 10.1111/j.1468-1331.2011.03521.x. Epub 2011 Sep 27.
Liang KG, Mu RZ, Liu Y, Jiang D, Jia TT, Huang YJ Increased Serum S100B Levels in Patients With Epilepsy: A Systematic Review and Meta-Analysis Study. Front Neurosci. 2019 May 16;13:456. doi: 10.3389/fnins.2019.00456. eCollection 2019.
Lin PT, Yu HY, Lu YJ, Wang WH, Chou CC, Hsu SPC, Lin CF, Lee CC Social functioning and health-related quality of life trajectories in people with epilepsy after epilepsy surgery. Epilepsy Behav. 2020 Feb;103(Pt A):106849. doi: 10.1016/j.yebeh.2019.106849. Epub 2019 Dec 27.
Liu Y, Ho RC, Mak A Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012 Aug;139(3):230-9. doi: 10.1016/j.jad.2011.08.003. Epub 2011 Aug 26.
Loscher W The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments. Neuropharmacology. 2020 May 1;167:107605. doi: 10.1016/j.neuropharm.2019.04.011. Epub 2019 Apr 11.
Luo Y, Hu Q, Zhang Q, Hong S, Tang X, Cheng L, Jiang L Alterations in hippocampal myelin and oligodendrocyte precursor cells during epileptogenesis. Brain Res. 2015 Nov 19;1627:154-64. doi: 10.1016/j.brainres.2015.09.027. Epub 2015 Oct 4.
Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007 May;48(5):1015-8. doi: 10.1111/j.1528-1167.2007.01022.x. Erratum In: Epilepsia. 2008 May;49(5):941.
Mohanraj R, Brodie MJ Early predictors of outcome in newly diagnosed epilepsy. Seizure. 2013 Jun;22(5):333-44. doi: 10.1016/j.seizure.2013.02.002. Epub 2013 Apr 11.
Musshoff F, Madea B Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006 Apr;28(2):155-63. doi: 10.1097/01.ftd.0000197091.07807.22.
Myers KA, Johnstone DL, Dyment DA Epilepsy genetics: Current knowledge, applications, and future directions. Clin Genet. 2019 Jan;95(1):95-111. doi: 10.1111/cge.13414. Epub 2018 Aug 2.
Nilsson FM, Kessing LV, Bolwig TG On the increased risk of developing late-onset epilepsy for patients with major affective disorder. J Affect Disord. 2003 Sep;76(1-3):39-48. doi: 10.1016/s0165-0327(02)00061-7.
Nimmo-Smith V, Brugha TS, Kerr MP, McManus S, Rai D Discrimination, domestic violence, abuse, and other adverse life events in people with epilepsy: Population-based study to assess the burden of these events and their contribution to psychopathology. Epilepsia. 2016 Nov;57(11):1870-1878. doi: 10.1111/epi.13561. Epub 2016 Sep 16.
Noebels J Pathway-driven discovery of epilepsy genes. Nat Neurosci. 2015 Mar;18(3):344-50. doi: 10.1038/nn.3933. Epub 2015 Feb 24.
Nogueira MH, Yasuda CL, Coan AC, Kanner AM, Cendes F Concurrent mood and anxiety disorders are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia. 2017 Jul;58(7):1268-1276. doi: 10.1111/epi.13781. Epub 2017 May 26.
Perucca E Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord. 2019 Aug 1;21(4):319-329. doi: 10.1684/epd.2019.1083.
Poldrack RA, Huckins G, Varoquaux G Establishment of Best Practices for Evidence for Prediction: A Review. JAMA Psychiatry. 2020 May 1;77(5):534-540. doi: 10.1001/jamapsychiatry.2019.3671.
Polley E, Van Der Laan M Super Learner in prediction. UC Berkeley Division of Biostatistics Working Paper Series. Working Paper 266, May 2010, http://biostats.bepress.com/ucbbiostat/paper266; 2010.
Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006 May;28(5):734-44. doi: 10.1016/j.clinthera.2006.05.004.
Ravizza T, Balosso S, Vezzani A Inflammation and prevention of epileptogenesis. Neurosci Lett. 2011 Jun 27;497(3):223-30. doi: 10.1016/j.neulet.2011.02.040. Epub 2011 Feb 26.
Salpekar JA, Mula M Common psychiatric comorbidities in epilepsy: How big of a problem is it? Epilepsy Behav. 2019 Sep;98(Pt B):293-297. doi: 10.1016/j.yebeh.2018.07.023. Epub 2018 Aug 25.
Scanlon C, Mueller SG, Cheong I, Hartig M, Weiner MW, Laxer KD Grey and white matter abnormalities in temporal lobe epilepsy with and without mesial temporal sclerosis. J Neurol. 2013 Sep;260(9):2320-9. doi: 10.1007/s00415-013-6974-3. Epub 2013 Jun 11.
Shorvon SD, Bermejo PE, Gibbs AA, Huberfeld G, Kalviainen R Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection. Epilepsy Behav. 2018 May;82:91-103. doi: 10.1016/j.yebeh.2018.01.039. Epub 2018 Mar 27.
Silvado CE, Terra VC, Twardowschy CA CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmgenomics Pers Med. 2018 Mar 29;11:51-58. doi: 10.2147/PGPM.S108113. eCollection 2018.
Strozzi I, Nolan SJ, Sperling MR, Wingerchuk DM, Sirven J Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2015 Feb 11;2015(2):CD001902. doi: 10.1002/14651858.CD001902.pub2.
Tomson T, Battino D, Perucca E Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019 Apr;32(2):246-252. doi: 10.1097/WCO.0000000000000659.
Umemori J, Winkel F, Didio G, Llach Pou M, Castren E iPlasticity: Induced juvenile-like plasticity in the adult brain as a mechanism of antidepressants. Psychiatry Clin Neurosci. 2018 Sep;72(9):633-653. doi: 10.1111/pcn.12683. Epub 2018 Jul 11.
Wang R, Zeng GQ, Liu X, Tong RZ, Zhou D, Hong Z Evaluation of serum matrix metalloproteinase-3 as a biomarker for diagnosis of epilepsy. J Neurol Sci. 2016 Aug 15;367:291-7. doi: 10.1016/j.jns.2016.06.031. Epub 2016 Jun 14.
Wang R, Zeng GQ, Tong RZ, Zhou D, Hong Z Serum matrix metalloproteinase-2: A potential biomarker for diagnosis of epilepsy. Epilepsy Res. 2016 May;122:114-9. doi: 10.1016/j.eplepsyres.2016.02.009. Epub 2016 Feb 27.
Wang X, Lv Y, Zhang W, Meng H Cognitive Impairment and Personality Traits in Epilepsy: Characterization and Risk Factor Analysis. J Nerv Ment Dis. 2018 Oct;206(10):794-799. doi: 10.1097/NMD.0000000000000880.
Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007 Feb;10(1):105-10. doi: 10.1016/j.yebeh.2006.08.008. Epub 2006 Oct 31.
Witt JA, Helmstaedter C Cognition in the early stages of adult epilepsy. Seizure. 2015 Mar;26:65-8. doi: 10.1016/j.seizure.2015.01.018. Epub 2015 Feb 7.
Witt JA, Helmstaedter C Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. J Neurol. 2012 Aug;259(8):1727-31. doi: 10.1007/s00415-012-6526-2. Epub 2012 May 12.
Wood SN Generalized additive models: an introduction with R: CRC press; 2017.
Xia L, Ou S, Pan S Initial Response to Antiepileptic Drugs in Patients with Newly Diagnosed Epilepsy As a Predictor of Long-term Outcome. Front Neurol. 2017 Dec 8;8:658. doi: 10.3389/fneur.2017.00658. eCollection 2017.
Yao L, Cai M, Chen Y, Shen C, Shi L, Guo Y Prediction of antiepileptic drug treatment outcomes of patients with newly diagnosed epilepsy by machine learning. Epilepsy Behav. 2019 Jul;96:92-97. doi: 10.1016/j.yebeh.2019.04.006. Epub 2019 May 20.
Yilmaz U, Yilmaz TS, Dizdarer G, Akinci G, Guzel O, Tekgul H Efficacy and tolerability of the first antiepileptic drug in children with newly diagnosed idiopathic epilepsy. Seizure. 2014 Apr;23(4):252-9. doi: 10.1016/j.seizure.2013.12.001. Epub 2013 Dec 9.
Zhang B, Chen M, Yang H, Wu T, Song C, Guo R Evidence for involvement of the CD40/CD40L system in post-stroke epilepsy. Neurosci Lett. 2014 May 1;567:6-10. doi: 10.1016/j.neulet.2014.03.003. Epub 2014 Mar 19.
Zhu X, He Z, Luo C, Qiu X, He S, Peng A, Zhang L, Chen L Altered spontaneous brain activity in MRI-negative refractory temporal lobe epilepsy patients with major depressive disorder: A resting-state fMRI study. J Neurol Sci. 2018 Mar 15;386:29-35. doi: 10.1016/j.jns.2018.01.010. Epub 2018 Jan 10.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.